Other Events ·
Scinai Immunotherapeutics Ltd. terminated its option and license arrangements for PC111 with PinCell S.r.l. after…
SCNIScinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. terminated its option and license arrangements for PC111 with PinCell S.r.l. after failing to reach an extension agreement before conditions expired on August 31, 2026. The company will refocus R&D resources on its NanoAb platform and CDMO business, citing the need to preserve capital in the absence of secured grant funding for PC111. Scinai is pursuing approximately €12 million in Polish grant financing for an intradermal IL-17 psoriasis program and has committed customer orders totaling $3.1 million as of August 16, 2026. The company aims to generate approximately $5 million in CDMO revenue for 2026 while advancing systemic IL-17 bispecific programs. Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on innovative immunology therapies and operates a contract development and manufacturing organization.